The messenger RNA drug developer, backed by Monsanto, Merck & Co, GlaxoSmithKline, Pfizer and Merck Group, has raised more than $121m in its initial public offering.
Translate Bio, a biopharmaceutical company backed by agribusiness Monsanto and pharmaceutical firms GlaxoSmithKline, Merck & Co, Pfizer and Merck Group, will raise more than $121m when it floats later today.
The company increased the number of shares in the initial public offering from 7.7 million to 9.35 million, and priced them at $13.00 each, in the middle of the IPO’s $12 to $14 range. It will float on the Nasdaq Global Select Market.
Formerly known as RaNA Therapeutics, Translate is…
